Alto Neuroscience, Inc. (NYSE:ANRO) Stake Raised by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 148.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 469,988 shares of the company’s stock after purchasing an additional 281,018 shares during the period. Geode Capital Management LLC’s holdings in Alto Neuroscience were worth $5,378,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. FMR LLC boosted its holdings in Alto Neuroscience by 1.4% during the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after buying an additional 32,040 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Alto Neuroscience by 80.3% during the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock valued at $9,521,000 after acquiring an additional 370,612 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Alto Neuroscience by 4.8% during the 3rd quarter. Vestal Point Capital LP now owns 650,000 shares of the company’s stock valued at $7,436,000 after acquiring an additional 30,000 shares during the last quarter. Philadelphia Financial Management of San Francisco LLC grew its holdings in shares of Alto Neuroscience by 1.5% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock worth $5,147,000 after acquiring an additional 6,663 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Alto Neuroscience by 123.7% in the 3rd quarter. State Street Corp now owns 236,857 shares of the company’s stock worth $2,710,000 after acquiring an additional 130,985 shares during the last quarter.

Alto Neuroscience Trading Up 5.3 %

Shares of NYSE:ANRO opened at $4.61 on Friday. The firm has a fifty day moving average of $4.15 and a two-hundred day moving average of $9.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. Alto Neuroscience, Inc. has a 12-month low of $3.56 and a 12-month high of $24.00.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. Equities analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ANRO shares. Stifel Nicolaus decreased their price target on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and cut their price target for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.